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Abstract
Background  and  objectives:  There  is  evidence  that  patients  with  irritable  bowel  syndrome  (IBS)
have a  low  degree  of  inﬂammation  in  the  intestinal  mucosa.  The  aim  of  the  study  was  to  evaluate
theproﬁle of  pro-  and  anti-inﬂammatory  cytokinesin  plasmain  Mexican  pediatric  patients  with
IBS.
Patients and  methods:  Fifteen  patients  with  IBS  according  to  Rome  III  criteria  for  childhood
and 15  healthy  children,  matched  by  age  and  sex,  were  included  in  the  study.  Plasma  levels  of
tumoral necrosis  factor  alpha  (TNF-),  interleukins  10  and  12  (IL-10,  IL-12)  and  transforming
growth factor  beta  (TGF-)  were  quantiﬁed  and  compared  between  groups.
Results: Plasma  levels  of  IL-10  were  lower  in  patients  with  IBS  (86.07  +  21.3  pg/mL  vs.
118.71 +  58.62  pg/mL:  P=.045)  and  IL-12  levels  were  higher  in  patients  with  IBS  compared  to  the
control group  of  healthy  children  (1,204.2  ±  585.9  pg/mL  vs.  655.04  ±  557.80  pg/mL;  P=.011).
The IL-10/IL-12  index  was  lower  in  patients  with  IBS  (0.097  ±  0.07  vs.  0.295  ±  0.336;  P=.025).
Plasma  concentration  of  TGF-  was  higher  in  patients  with  IBS  (545.67  ±  337.69  pg/mL  vs.
208.48 ±  142.21  pg/mL;  P=.001).  There  was  no  difference  in  plasma  levels  of  TNF-  between
groups.
 Please cite this article as: Vázquez-Frias R, Gutiérrez-Reyes G, Urbán-Reyes M, Velázquez-Guadarrama N, Fortoul-van der Goes TI, Reyes-
ópez A, et al. Perﬁl de citocinas proinﬂamatorias y antiinﬂamatorias en pacientes pediátricos con síndrome de intestino irritable. Revista
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Conclusions:  This  study  suggests  that  children  with  IBS  have  a  state  of  altered  immune  regu-
lation. This  is  consistent  with  the  theory  of  low-grade  inﬂammatory  state  in  these  patients.
Further studies  are  needed  to  elucidate  the  role  played  by  these  cytokines,  speciﬁcally  TGF-
in the  pathogenesis  of  IBS.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Perﬁl  de  citocinas  proinﬂamatorias  y  antiinﬂamatorias  en  pacientes  pediátricos  con
síndrome  de  intestino  irritable
Resumen
Antecedentes  y  objetivos:  Existe  evidencia  de  un  grado  bajo  de  inﬂamación  a  nivel  de  la  mucosa
intestinal en  pacientes  con  síndrome  de  intestino  irritable  (SII).  El  objetivo  del  estudio  fue  eval-
uar el  perﬁl  de  citocinas  proinﬂamatorias  y  antinﬂamatorias  en  plasma  en  pacientes  pediátricos
mexicanos  con  SII.
Pacientes  y  métodos: Quince  pacientes  con  SII  de  acuerdo  con  los  criterios  de  Roma  III  para
pacientes  pediátricos  y  15  nin˜os  sanos,  pareados  por  edad  y  sexo  fueron  incluidos  en  el  estudio.
Se cuantiﬁcaron  en  plasma  y  se  compararon  el  factor  de  necrosis  tumoral  alfa  (TNF-),  las
interleucinas  10  y  12  (IL-10,  IL-12)  y  el  factor  de  crecimiento  transformante  beta  (TGF-).
Resultados:  Los  niveles  plasmáticos  de  IL-10  fueron  menores  en  los  pacientes  con  SII
(86.07 +  21.3  pg/mL  vs.  118.71  +  58.62  pg/mL;  p  =  0.045)  y  los  niveles  de  IL-12  mayores  en  los
pacientes con  SII  en  comparación  con  el  grupo  control  de  nin˜os  sanos  (1,204.2  ±  585.9  pg/mL
vs. 655.04  ±  557.80  pg/mL;  p  =  0.011).  El  índice  IL-10/IL-12  fue  menor  en  los  pacientes  con  SII
(0.097 ±  0.07  vs.  0.295  ±  0.336;  p  =  0.025).  La  concentración  en  plasma  de  TGF-  fue  mayor  en
los pacientes  con  SII  (545.67  ±  337.69  pg/mL  vs.  208.48  ±  142.21  pg/mL;  p  =  0.001).  No  hubo
diferencia  en  los  niveles  plasmáticos  de  TNF-  entre  ambos  grupos.
Conclusiones:  Este  estudio  indica  que  los  nin˜os  con  SII  presentan  un  estado  de  alteración  de
la regulación  inmune.  Aún  está  pendiente  por  dilucidar  el  papel  que  juegan  estas  citocinas,
especíﬁcamente  la  TGF-,  en  la  patogénesis  del  SII.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Irritable  bowel  syndrome  (IBS)  is  a  functional  gastrointesti-
nal  disorder  that  is  deﬁned  by  the  Rome  III  criteria  for
pediatric  patients  as  the  sensation  of  abdominal  discomfort
or  pain  that  has  presented  at  least  once  a  week  in  the  2
months  prior  to  diagnosis  and  is  associated  with  2  of  the  fol-
lowing  characteristics  at  least  25%  of  the  time:  a)  it  improves
with  a  bowel  movement,  b)  onset  is  associated  with  changes
in  bowel  movement  frequency,  and  c)  onset  is  associated
with  change  in  the  form  (appearance)  of  the  bowel  move-
ments.  There  is  no  evidence  of  an  inﬂammatory,  anatomic,
metabolic,  or  neoplastic  process  accompanying  these  char-
acteristics  and  they  should  also  be  present  at  least  once  a
week  in  the  2  months  before  diagnosis.1 Between  22-45%  of
the  pediatric  patients  from  4  to  18  years  of  age  that  are
seen  at  tertiary  care  clinics  are  diagnosed  with  IBS.  Multi-
ple  mechanisms  are  involved  in  its  pathophysiology.  One  of
the  ﬁrst  studied  is  visceral  hypersensitivity,  a  consequence
of  an  alteration  in  the  brain-bowel  axis  that  most  likely  is
modulated  by  genetic  factors  that  regulate  the  local  inﬂam-
matory  and  immunologic  responses  to  different  processes
h
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euch  as  infections,  intestinal  trauma,  or  allergy.  These,  in
urn,  cause  intestinal  motility  disorders  that  clinically  man-
fest  as  diarrhea  or  constipation,  associated  or  not,  with
bdominal  pain.2--5 However,  psychologic  and  inﬂammatory
actors,  as  well  as  motility  alterations  also  come  into  play
n  relation  to  its  pathophysiology.
An infectious  event  can  apparently  precipitate  IBS  devel-
pment  in  individuals  with  a  psychosocial  and  genetic
usceptibility,  probably  by  conditioning  a  mild  grade  of
ntestinal  mucosa  inﬂammation  that  leads  to  immune  sys-
em  activation.4,6--8 Recent  studies  support  the  hypothesis  of
mmune  activation  in  adults  with  this  syndrome:  inﬁltration
f  immune  cells  into  the  intestinal  mucosa  of  IBS  patients9--11
nd  a  greater  expression  of  proinﬂammatory  cytokines,  such
s  interleukin  (IL)-6,  IL-8,  tumor  necrosis  factor  (TNF)-,  and
L-12,  with  low  levels  of  IL-10.12--16 Polymorphisms  of  a  sin-
le  nucleotide  in  the  genes  that  encode  for  TNF- and  IL-10
ave  been  reported  in  adult  IBS  patients,  compared  with
ealthy  controls.12,17,18 Hua  et  al.  recently  found  that  IL-10
evels  were  lower  in  pediatric  IBS  patients  when  compared
ith  healthy  controls;  they  found  no  differences  in  the  lev-
ls  of  TNF and  IL-6,  both  proinﬂammatory  cytokines,  but
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hese  have  not  been  evaluated  in  the  Latin  population.19
he  aim  of  our  study  was  to  analyze  the  proinﬂammatory
nd  anti-inﬂammatory  cytokine  proﬁle  in  pediatric  patients
resenting  with  IBS  at  a  tertiary  care  center.  The  study
ypothesis  was  that  Mexican  children  with  IBS  would  present
ith  lower  plasma  levels  of  IL-10  and  higher  plasma  levels
f  IL-12  and  TNF-.
ethods
tudy  population
wo  researchers  recruited  the  IBS  patients  from  the
utpatient  consultation  service  of  the  Department  of  Gas-
roenterology  and  Nutrition  of  the  Hospital  Infantil  de
éxico  Federico  Gómez  and  the  healthy  controls  from
chools  in  Mexico  City  and  its  suburbs  (RVF  and  ACS).  The
on-probability  convenience  sampling  technique  was  used
o  create  the  study  group  and  the  controls.  All  the  parti-
ipants  were  residents  of  Mexico  City  and  its  Metropolitan
rea.
The  IBS  patients  were  diagnosed  according  to  the  Rome
II  criteria  for  pediatric  patients:  sensation  of  abdominal
iscomfort  or  pain  that  presented  at  least  once  a week
n  the  2  months  prior  to  diagnosis,  associated  with  2  of
he  following  characteristics  at  least  25%  of  the  time:  a)
t  improves  with  a  bowel  movement,  b)  onset  is  asso-
iated  with  changes  in  bowel  movement  frequency,  and
)  onset  is  associated  with  change  in  the  form  (appear-
nce)  of  the  bowel  movements.  There  is  no  evidence  of
n  inﬂammatory,  anatomic,  metabolic,  or  neoplastic  pro-
ess  accompanying  these  characteristics  and  they  should
lso  be  present  at  least  once  a  week  in  the  2  months  before
iagnosis.1
No  patients  or  controls  were  included  in  the  study  if  they
resented  with  malnutrition  or  overweight  according  to  the
orld  Health  Organization  and  Centers  for  Disease  Control
ables,  with  any  infectious  gastrointestinal  process,  if  they
ere  carriers  of  any  known  allergic  or  immune  alteration,
r  if  they  had  received  antibiotics,  probiotics,  analgesics,  or
nti-inﬂammatory  agents  in  the  month  prior  to  their  recruit-
ent.  A  hemogram,  blood  chemistry  test,  3-sample  stool  ova
nd  parasite  exam,  fecal  Giardia  intestinalis  antigen  test,
nd  a  urinalysis  were  ordered  for  all  the  participants,  none
f  which  showed  any  alterations.
valuation  of  symptomatology
ymptomatology  was  present,  through  questioning,  for  at
east  4  months  prior  to  the  study  (4-37  month  interval).  To
emonstrate  the  characteristics  of  their  symptoms  and  cor-
oborate  the  IBS  diagnosis  for  pediatric  patients  according
o  the  Rome  III  criteria,  all  the  IBS  patients  or  their  rela-
ives  ﬁlled  out  a  symptoms  diary  at  least  2  months  prior  to
heir  enrollment.  They  kept  a  daily  record  of  the  presence
r  absence  of  symptoms  such  as  abdominal  discomfort  or
ain,  abdominal  bloating,  and  bowel  movement  frequency
nd  characteristics.
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ample  collection  and  the  enzymatic  immunoassay
rocess
 10  ml  venous  blood  sample  was  collected  in  tubes  with
nticoagulant.  The  samples  were  centrifuged  at  400xg  for
0  min  to  obtain  plasma,  which  was  then  stored  at  −70 ◦C
ntil  its  use.  The  plasma  levels  of  the  TNF, IL-12,  IL-10,
nd  TGF- cytokines  were  quantiﬁed  in  duplicate  utilizing
ommercial  kits  (EIA)  (Assay  Designs  TiterZyme®EIA,  Inc.
nn  Arbor,  MI,  USA),  following  the  manufacturer’s  instruc-
ions.  Optic  density  was  measured  at  a  450  nm  wavelength
ith  a  620  nm  reference  wavelength,  utilizing  an  ELISA
icroplate  reader  (Multiskan  FC,  Thermo  Fisher  Scientiﬁc
y  Microplate  Instrumentation  Ratastie  2,  P.O.  Box  100  Van-
aa,  Finland).  The  values  obtained  were  correlated  linearly
ith  the  standard  concentrations,  forming  the  calibration
urve  for  each  cytokine.  The  sensitivity  limit  for  each  assay
as  the  following:  TNF-: 8.43  pg/mL,  IL-10:  3.75  pg/mL,
GF-:  3.3  pg/mL,  and  IL-12:  0.9  pg/mL.  The  samples  were
un  in  duplicate.
tatistical  analysis
aking  into  account  the  difference  found  between  the  levels
f  the  IL-10  (exempliﬁed)  and  IL-12  cytokines  in  a  previous
tudy  on  adults  by  OM´ahony  et  al.,16 we  made  a sample  cal-
ulation  using  the  mean  of  the  2  groups  with  an  alpha  value
f  0.05  and  a power  of  95%.  We  applied  the  formula  for  com-
aring  the  means  of  the  2  samples,  and  using  a  two-tailed
ample,  obtained  5  cases  per  group;  considering  the  differ-
nces  in  the  IL-10/IL-12  index,  an  n  of  one  per  group  was
gured;  and  allowing  for  the  differences  found  for  TNF-
ith  the  same  alpha  and  power  resulted  in  8  patients  per
roup.  The  decision  was  made  to  include  15  patients  in  each
roup.
The  plasma  levels  of  the  interleukins  (pg/mL)  of  both
roups  were  analyzed  through  the  Shapiro-Wilk  test  to
etermine  if  they  had  a  normal  distribution.  Upon  ﬁnding
hat  the  normality  criteria  were  not  met,  the  nonparamet-
ic  Mann-Whitney  U  test  was  applied  for  independent  group
valuation.  A  power  calculation  of  the  differences  was  car-
ied  out  to  establish  the  probabilities  of  committing  a  type
I  error.  The  statistical  calculations  were  made  using  the
indows  SPSS  16.0  program  (SPSS  Inc,  Chicago,  IL,  USA).
Our  study  was  approved  by  the  Research  Commission  and
he  Ethics  Committee  of  the  Hospital  Infantil  de  México  Fed-
rico  Gómez.  The  parents  of  all  the  study  participants  gave
heir  informed  consent  and  the  participants  above  8  years
f  age  signed  statements  of  informed  consent.
esults
emographic  data  and  clinical  characteristics
ifteen  patients  with  IBS  were  included  in  the  study;  8
ere  girls  (53%).  The  mean  age  was  10.5  ±  3.9  years,  with median  age  of  10.5  years  (6-17  year  interval).  According
o  IBS  subtype,  8  patients  (53%)  presented  with  the  mixed
ubtype  (IBS-M),  4  (26%)  with  diarrhea  (IBS-D),  and  3  (20%)
ith  constipation  (IBS-C).
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Table  1  Cytokine  plasma  levels  in  IBS  patients  and  controls.
Interleukin  IBS  Control  p  Power
IL-10  (pg/mL)  86.07  ±  21.3  118.71  ±  58.62  0.045  0.999
IL-12 (pg/mL)  1,204.2  ±  585.9  655.04  ±  557.80  0.011  1
IL-10/IL-12 index  0.097  ±  0.070  0.295  ±  0.336  0.025  0.999
TNF- (pg/mL)  276.23  ±  266.40  174.08  ±  189.42  0.218  0.878
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In  regard  to  the  healthy  controls,  15  children  and  ado-
lescents,  that  included  8  girls  (53%),  had  a  mean  age  of
11.4  ±  3.2  years  and  a  median  age  of  10.75  years  (6.1-17.3
year  interval).  There  were  no  signiﬁcant  basal  differences
in  relation  to  sex  and  age  between  the  groups.
Interleukin  plasma  levels
IL-10  levels  were  lower  (p  =  0.045)  and  IL-12  levels  were
higher  (p  =  0.011)  in  the  IBS  patients  than  in  the  controls
(p  =  0.011).  The  IL-10/IL-12  index  was  lower  in  the  patients
with  IBS  (p  =  0.025).  Concerning  the  plasma  levels  of  TNF-
,  there  was  no  difference  between  the  groups  (p  =  0.218).
The  mean  TGF- concentration  in  plasma  was  higher  in  the
patients  with  IBS  (p  =  0.001).  These  results  are  shown  in
Table  1.
Discussion
IBS  is  a  functional  gastrointestinal  disorder  that  presents  in
both  the  adult  and  pediatric  populations.  IBS  prevalence  in
the  pediatric  population  ranges  from  14  to  21%,  depending
on  the  criteria  used  for  deﬁning  its  presence.1 In  Mexico
the  estimated  prevalence  is  between  16  and  35.5%  in  adult
populations.20,21 The  study  by  Schmulson  et  al.  with  adult
volunteers  from  Mexico  City  showed  a  prevalence  of  35.5%,
almost  2-fold  greater  than  that  reported  in  an  open  popula-
tion  (16%),  with  a  woman:man  (W:M)  ratio  of  4:1.27.20 There
are  no  available  data  on  prevalence  in  pediatric  patients  in
Mexico.
The  causes  of  IBS  are  not  completely  understood,  but
there  is  evidence  of  the  participation  of  multiple  patho-
physiologic  mechanisms,  all  of  which  are  interrelated.  They
include  genetic  and  psychosocial  factors,  visceral  hyper-
sensitivity,  motility  alterations,  intestinal  permeability,  and
inﬂammation.1,22--24
A  potential  explanation  of  IBS  pathophysiology  is  the
low-grade  inﬂammation  status  of  the  intestinal  mucosa.25
Intestinal  inﬂammatory  states,  regardless  of  the  speciﬁc
events  responsible  for  their  onset,  share  common  immuno-
logic  pathways  that  mediate  tissue  damage  and  repair.
There  is  evidence  that  lends  support  to  this  theory  of  low-
grade  inﬂammation,  as  demonstrated  in  a  recent  systematic
review  on  the  participation  of  the  inﬂammatory  processes  at
the  level  of  the  intestinal  mucosa.26 This  review  describes
the  numerous  studies  reporting  that  inﬂammatory  cells,
such  as  activated  mast  cells  and  B  and  T  lymphocytes,  are
higher  than  normal  in  number  in  the  mucosa  of  a  group
of  IBS  patients.  Data  also  suggest  that  there  is  a  state  of
immunologic  activation  manifested  by  increased  cytokine
i
p
c208.48  ±  142.21  0.001  1
roduction  at  the  level  of  the  mucosa,  blood,  and  feces,
hich  can  be  a  product  of  the  activation  of  mast  cells  and
ther  immune  system  cells.25 However,  it  is  very  unlikely
hat  these  are  the  only  alterations  responsible  for  IBS  etiol-
gy.
Cytokines  are  proteins  produced  by  the  activation  of
mmunologic  cells  that  inﬂuence  the  activity,  differenti-
tion,  and  proliferation  of  other  cells,  modulating  the
nnate  and  adaptive  immune  response.27 It  is  known  that
hese  proteins  play  an  important  role  in  the  pathogenesis
f  inﬂammatory  bowel  disease,  which  is  the  most  severe
tate  of  intestinal  inﬂammation,  but  they  also  inﬂuence
ther  states  of  tissular  damage,  such  as  infectious  ente-
ocolitis,  celiac  disease,  eosinophilic  gastroenteritis,  and
hey  have  recently  been  described  in  IBS.26,28,29 Their  pres-
nce  is  also  found  in  many  other  diseases  outside  of  the
astrointestinal  tract  that  involve  infectious,  allergic,  or
utoimmune  inﬂammatory  phenomena.  These  cytokines  are
resent  in  the  gastrointestinal  mucosa,  blood  (monocytes
nd  plasma),  and  feces,  and  can  be  measured  in  these  tissues
r  samples.16,19,24,29 Cytokines  can  inﬂuence  the  function  of
he  epithelial  cells,  smooth  muscle  cells,  and  the  enteric
ervous  system.  Changes  in  the  cytokine  proﬁle  of  patients
ith  IBS  can  exacerbate  changes  in  secretion,  permeability,
otility,  and  intestinal  sensitivity,  and  produce  symptoms  of
BS.19,24,30,31
A  clear  cytokine  proﬁle  in  blood  in  patients  with  IBS  does
ot  yet  exist.  Results  are  not  consistent  in  all  the  studies,
hich  could  be  the  result  of  measuring,  methodology,  and
tudy  population  differences.32,33 A  decrease  in  the  levels  of
nti-inﬂammatory  cytokines,  such  as  IL-10,  has  been  shown
n  adult  IBS  patients,  as  well  as  an  increase  in  the  proin-
ammatory  cytokines,  such  as  TNF-, IL-6,  IL-8,  and  IL-12,
isplaying  a  proinﬂammatory  proﬁle  in  these  patients.16,33--35
In  a  study  on  adult  patients,  the  cytokine  level  in  the
upernatant  from  a  non-stimulated  monocyte  culture  was
easured  and  showed  a  lower  IL-10  concentration  and  a
igher  IL-12  concentration  in  patients  with  IBS,  compared
ith  healthy  subjects;  and  the  IL-10/IL-12  index  was  lower
n  the  IBS  group.16 However,  a  recent  study  conducted  on
9  adults  with  IBS  and  34  healthy  controls  showed  no  differ-
nces  with  respect  to  IL-1  , IL-6,  IL-8,  IL-10,  IL-12,  or  TNF-
n  serum  levels  or  in  the  colonic  mucosa;  there  was  only  a
ifference  at  the  level  of  the  messenger  RNA  of  IL-10  in  the
olonic  mucosa  in  the  subgroup  of  female  patients.36 In  the
exican  adult  population,  low  levels  of  serum  IL-10  were
hown  in  IBS  patients  compared  with  healthy  controls.35At  the  time  our  study  was  conducted  there  was  no
nformation  on  the  proﬁle  of  these  cytokines  in  pediatric
atients.  A  recently  published  study  that  measured  the
ytokines  in  the  supernatant  of  a  non-stimulated  peripheral
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lood  mononuclear  cell  (PBMC)  culture  with  lipopolysaccha-
ides  from  Escherichia  coli  showed  that  IL-10  levels  were
ower  in  pediatric  patients  with  IBS  (82.6  ±  46.41  pg/mL),
ompared  with  healthy  controls  (214.65  ±  76.23).  The  lev-
ls  in  both  groups  were  very  similar  to  those  found  in  our
tudy.19
The  low  IL-10  levels  found  in  our  population  of  children
ith  IBS,  compared  with  healthy  controls,  are  consistent
ith  those  found  in  other  studies  on  the  adult  population,
ncluding  Mexican  adults,  as  well  as  in  another  pediatric
tudy.16,19,35 Likewise,  IL-12  levels  were  also  increased  in
ur  group  with  IBS,  similar  to  that  reported  in  the  adult
opulation.16
Unlike  the  studies  on  adults,  including  those  on  Mexican
atients,  our  study  did  not  show  a  difference  in  the  plasma
evels  of  TNF- in  the  pediatric  population.35,37 Neverthe-
ess,  it  is  striking  that  very  high  levels  of  TNF- were  found
n  both  groups  of  children,  compared  with  that  reported
n  another  study  that  also  measured  TNF- plasma  levels,
ven  though  the  study  was  conducted  on  adult  women  that
ad  other  comorbidities.38 In  a  study  by  Hua  et  al.  on  a
ediatric  population,  they  also  found  very  high  levels  of
NF-  in  a  supernatant  of  a  PBMC  culture,  but  unlike  our
tudy  that  measured  plasma  levels,  they  found  differences
etween  the  2  groups,  with  higher  levels  in  the  children
ith  IBS.19 Another  report  on  adult  patients  showed  no
vidence  of  a  difference  in  TNF- between  the  2  groups,
ut  it  corresponded  to  measurements  of  a  supernatant  of
 monocyte  culture  stimulated  by  lipopolysaccharides  for
2  h  prior  to  measurement;  the  authors  commented  that
heir  results  were  probably  related  to  the  limited  num-
er  of  patients  in  their  study.39 It  is  known  that  TNF-
as  a  proinﬂammatory  effect  and  it  has  been  clearly  impli-
ated  as  a  trigger  of  the  septic  phenomenon  by  increasing
he  plasma  concentrations  of  small  mediating  molecules
uch  as  the  platelet-activating  factor,  prostaglandins,  and
itric  oxide.  In  relation  to  the  participation  of  TNF- in
BS,  in  addition  to  its  being  found  in  higher  levels  in
dults  with  IBS,  compared  with  controls,  both  in  serum
nd  in  the  supernatant  of  non-activated  polymorphonuclear
ells,  other  studies  have  also  reported  that  the  combined
ossession  of  the  high  producer  TNF- genotype  (G/A  het-
rozygotes)  and  the  low  producer  IL-10  genotype  is  a  risk
actor  for  IBS,  given  that  this  combination  was  signiﬁcantly
ore  prevalent  in  the  subjects  with  IBS,  mainly  those  with
BS-D.17,20 However,  in  a  study  on  Mexican  adult  volunteers,
o  differences  in  the  lL-10  (-1082G/A)  or  TNF- (-308G/C)
enotypes  were  found  between  the  subjects  with  IBS  and
he  controls.40
To  the  best  of  our  knowledge,  no  reports  have  measured
he  plasma  levels  of  TGF- in  pediatric  or  adult  patients
ith  IBS;  we  decided  to  measure  it  because  it  is  an  impor-
ant  immune  response  modulator.  Our  study  showed  higher
lasma  levels  of  TGF- in  the  patients  with  IBS,  compared
ith  the  controls.  The  speciﬁc  role  that  TGF- has  in  the
athogenesis  of  IBS  is  not  known.  Even  though  a  study  on
dult  patients  did  not  show  any  differences  in  the  frequen-
ies  of  genotypes  for  TGF- between  patients  with  IBS  and
ealthy  controls,6 it  is  thought  that  TGF- could  be  involved
n  the  pathophysiology  of  IBS.  There  is  evidence  that  TGF-
articipates  in  the  pathophysiology  of  inﬂammatory  bowel
isease,  speciﬁcally  Crohn’s  disease.  It  acts  together  with
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L-6  as  an  inducer  of  Th-17  cells,  which  produce  IL-17  and
L-22  implicated  in  the  production  of  inﬂammation  at  the
issular  level;  the  Th-17  cells  are  then  modulated  by  IL-
3.  There  is  also  evidence  that  the  differentiation  of  Th-17
ells  in  the  absence  of  IL-23  leads  to  IL-10  production,  which
s  why  these  cells  are  poor  inducers  of  inﬂammation.  Th17
ells  require  TGF- for  their  differentiation.  In  addition,  T
ells  produce  large  quantities  of  TGF- and  they  can  induce
aive  CD4  +  cells  to  produce  IL-17  and  can  themselves  be
onverted  into  Th17  cells.29 Furthermore,  the  data  obtained
rom  the  study  by  Gebhardt  et  al.  indicate  that  TGF-1 acts
s  a potent  inhibitor  and  modulator  of  mast  cells,  in  such
 way  that  the  study  conﬁrms  what  has  been  referred  to
n  other  articles,  about  the  fact  that  TGF-1 is  an  anti-
nﬂammatory  cytokine  that  is  constitutively  expressed  in  the
ntestine.41 The  plasma  levels  of  TGF- that  we  found  in  our
tudy  could  be  increased  as  a  response  to  the  proinﬂam-
atory  state  that  IBS  patients  present.  However,  the  role
hat  TGF- plays  in  the  pathogenesis  of  IBS  is  still  to  be
eﬁned.
The  cytokine  levels  shown  in  our  study,  in  the  IBS  patients
s  well  as  the  controls,  are  very  high  in  comparison  with
ther  similar  studies.  However,  this  is  probably  due  to  the
ype  of  commercial  kit  utilized.  One  study  conducted  on
regnant  women,  speciﬁcally  during  their  ﬁrst  trimester,
n  which  TNF- levels  were  determined,  reported  that  one
f  the  assays  employed  (Pierce®)  showed  levels  using  1  to
-digit  ﬁgures  (4.23  pg/mL;  1.34  --77.2  pg/mL  interval),
hereas  the  measurements  with  TiterZyme®,  the  same  kit
mployed  in  our  study,  were  expressed  with  2  to  3-digit  ﬁg-
res  (176.96  pg/mL;  54.7-283.9  pg/mL),  in  ranges  similar  to
hose  of  our  study.42 A  Colombian  study  carried  out  on  obese
nd  eutrophic  children,  utilizing  another  commercial  kit,
howed  TNF- levels  in  three-digit  ﬁgures,  with  a  wide  stan-
ard  deviation  (210.27  + 281.96  pg/mL  vs  284.28  +  384.99,
espectively).43 It  is  feasible  that  the  very  high  results  found
n  the  2  groups  of  our  study  are  secondary  to  the  type
f  commercial  kit  used,  making  the  comparison  with  other
tudies  difﬁcult.
Our  study  has  the  following  limitations:  IBS  subtype  com-
arisons  could  not  be  made  because  of  the  small  sample  size;
he  study  was  carried  out  on  patients  that  were  seen  at  a
ertiary  care  hospital,  rather  than  on  an  open  population,
nd  therefore  our  results  cannot  be  generalized;  celiac  dis-
ase  was  not  ruled  out  appropriately  in  all  the  patients;  and
nally,  cytokine  measurement  was  not  made  directly  from
he  colonic  mucosa  to  determine  if  it  was  correlated  with
he  serum  levels.
onclusions
ur  results  showed  that  children  with  IBS  presented  with  an
ltered  immune  regulation  state  by  showing  plasma  levels
hat  were  lower  for  IL-10  and  higher  for  IL-12.  No  difference
n  TNF- levels  was  found  between  the  2  groups.  TGF- lev-
ls  were  higher  in  the  patients  with  IBS,  but  the  role  this
lays  in  IBS  pathogenesis  remains  to  be  determined.  These
esults  suggest  that  the  alteration  in  immune  system  mod-
lation  may  be  participating  in  the  development  of  IBS  in
hildren.
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